P53 and E2f: Partners in Life and Death

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2009 Sep 25

PMID 19776743

Citations 262

Authors

Shirley Polager

Doron Ginsberg

Affiliations

Soon will be listed here.

Abstract

During tumour development cells sustain mutations that disrupt normal mechanisms controlling proliferation. Remarkably, the Rb-E2f and MDM2-p53 pathways are both defective in most, if not all, human tumours, which underscores the crucial role of these pathways in regulating cell cycle progression and viability. A simple interpretation of the observation that both pathways are deregulated is that they function independently in the control of cell fate. However, a large body of evidence indicates that, in addition to their independent effects on cell fate, there is extensive crosstalk between these two pathways, and specifically between the transcription factors E2F1 and p53, which influences vital cellular decisions. This Review discusses the molecular mechanisms that underlie the intricate interactions between E2f and p53.

Citing Articles

CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma.

Xiong Y, Lei J, Wen M, Ma Y, Zhao J, Tian Y Oncogenesis. 2025; 14(1):5.

PMID: 40044674 PMC: 11882812. DOI: 10.1038/s41389-025-00546-5.

KRAS-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC.

Jiang X, Wang T, Zhao B, Sun H, Dong Y, Ma Y Cell Rep Med. 2025; 6(2):101966.

PMID: 39970873 PMC: 11866490. DOI: 10.1016/j.xcrm.2025.101966.

DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53.

Nakajima R, Zhou Y, Shirasawa M, Nishimura N, Zhao L, Fikriyanti M Int J Mol Sci. 2025; 25(24.

PMID: 39769018 PMC: 11675670. DOI: 10.3390/ijms252413251.

Acetylation of E2F1 at K125 facilitates cell apoptosis under serum stress.

Fang Z, Gong C, Hu Y, Cui T, Lin M, Lin S Transl Oncol. 2024; 52():102259.

PMID: 39731810 PMC: 11743828. DOI: 10.1016/j.tranon.2024.102259.

TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond.

Wu Q, Nandi D, Sharma D Cancer Metastasis Rev. 2024; 44(1):16.

PMID: 39644332 PMC: 11625080. DOI: 10.1007/s10555-024-10226-2.

References

OConnor D, Lu X . Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene. 2000; 19(20):2369-76. DOI: 10.1038/sj.onc.1203540. View

Tolbert D, Lu X, Yin C, Tantama M, Van Dyke T . p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol. 2001; 22(1):370-7. PMC: 134227. DOI: 10.1128/MCB.22.1.370-377.2002. View

OConnor D, Bergamaschi D, Trigiante G, Hsieh J, Zhong S, Campargue I . ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001; 8(4):781-94. DOI: 10.1016/s1097-2765(01)00367-7. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Lin W, Lin F, Nevins J . Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001; 15(14):1833-44. PMC: 312742. View

Fogal V, Kartasheva N, Trigiante G, Llanos S, Yap D, Vousden K . ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ. 2005; 12(4):369-76. DOI: 10.1038/sj.cdd.4401562. View

Moroni M, Hickman E, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F . Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001; 3(6):552-8. DOI: 10.1038/35078527. View

Saavedra H, Wu L, de Bruin A, Timmers C, Rosol T, Weinstein M . Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ. 2002; 13(5):215-25. View

Rogoff H, Pickering M, Frame F, Debatis M, Sanchez Y, Jones S . Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol. 2004; 24(7):2968-77. PMC: 371110. DOI: 10.1128/MCB.24.7.2968-2977.2004. View

10.

Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y . Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006; 8(9):1025-31. DOI: 10.1038/ncb1468. View

11.

Rogoff H, Pickering M, Debatis M, Jones S, Kowalik T . E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol. 2002; 22(15):5308-18. PMC: 133953. DOI: 10.1128/MCB.22.15.5308-5318.2002. View

12.

Fuster J, Sanz-Gonzalez S, Moll U, Andres V . Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med. 2007; 13(5):192-9. DOI: 10.1016/j.molmed.2007.03.002. View

13.

Levine A . The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology. 2008; 384(2):285-93. DOI: 10.1016/j.virol.2008.09.034. View

14.

Nahle Z, Polakoff J, Davuluri R, McCurrach M, Jacobson M, Narita M . Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol. 2002; 4(11):859-64. DOI: 10.1038/ncb868. View

15.

Ianari A, Gallo R, Palma M, Alesse E, Gulino A . Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem. 2004; 279(29):30830-5. DOI: 10.1074/jbc.M402403200. View

16.

Zhang L, Wang C . F-box protein Skp2: a novel transcriptional target of E2F. Oncogene. 2005; 25(18):2615-27. PMC: 1513044. DOI: 10.1038/sj.onc.1209286. View

17.

Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H . Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell. 2008; 14(1):62-75. PMC: 2253677. DOI: 10.1016/j.devcel.2007.10.017. View

18.

Sherr C, McCormick F . The RB and p53 pathways in cancer. Cancer Cell. 2002; 2(2):103-12. DOI: 10.1016/s1535-6108(02)00102-2. View

19.

Feber A, Clark J, Goodwin G, Dodson A, Smith P, Fletcher A . Amplification and overexpression of E2F3 in human bladder cancer. Oncogene. 2004; 23(8):1627-30. DOI: 10.1038/sj.onc.1207274. View

20.

Weisz L, Oren M, Rotter V . Transcription regulation by mutant p53. Oncogene. 2007; 26(15):2202-11. DOI: 10.1038/sj.onc.1210294. View